Congress shields rare-disease drugs from Medicare price negotiation

What it does

This bill exempts orphan drugs (medications for rare diseases) from Medicare's drug price negotiation program by raising their eligibility threshold from $200 million to $400 million in annual sales. Only drugs meeting the higher threshold can be negotiated; orphan drugs stay protected from price negotiation, preserving higher prices for rare-disease treatments starting in 2028.

Why we flagged it

The bill's operative mechanism is a targeted exemption for orphan drugs from Medicare price negotiation, achieved by doubling the sales threshold. This is a direct financial protection for pharmaceutical manufacturers of rare-disease treatments, not a public-health measure.

What the text implies

• The $400M threshold may capture drugs beyond true orphan-drug status if a manufacturer structures indications narrowly; the bill does not limit the number of rare conditions a drug can treat, only that ALL approved indications must be rare.
• Delayed application (2028 start) allows current orphan drugs to remain negotiated under existing rules for 3+ years, then grandfathers them out—creating a cliff that may incentivize manufacturers to seek orphan designation before the cutoff.
• The bill does not define 'rare disease' itself; it cross-references FDA's definition in 21 U.S.C. § 526(a)(2), which covers conditions affecting fewer than 200,000 Americans. A drug can qualify even if it treats multiple rare conditions, potentially broadening the exemption beyond single-indication orphans.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries and taxpayers will pay higher prices for orphan drugs because the bill shields them from price negotiation. While rare-disease patients may benefit from continued drug development incentives, the direct effect is that Medicare cannot negotiate prices downward, shifting costs to seniors and the federal program.

Who stands to gain

• pharmaceutical manufacturers of orphan drugs
• biotech companies with rare-disease pipelines

Named in the bill

Medicare, Social Security Act § 1192(e), Federal Food, Drug, and Cosmetic Act § 526(a)(2), FDA, CMS

Where it stands

2 cosponsors: 2 Democrats.

• Oct 21, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Oct 21, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $2,753,000 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Peter Welch, the sponsor, reported $44,000 in PAC receipts in the 2026 cycle.

• Amgen Inc — $2,440,000 on 1 filing
• Harmony Biosciences — $180,000 on 1 filing
• Public Citizen — $73,000 on 1 filing
• Bristol-myers Squibb Company — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.